These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7059462)

  • 21. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
    Pezzoni G; Grandi M; Biasoli G; Capolongo L; Ballinari D; Giuliani FC; Barbieri B; Pastori A; Pesenti E; Mongelli N
    Br J Cancer; 1991 Dec; 64(6):1047-50. PubMed ID: 1764367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of cure of large plasma cell tumors.
    Whisson ME; Connors TA; Jeney A
    Arch Immunol Ther Exp (Warsz); 1966; 14(6):825-31. PubMed ID: 5958003
    [No Abstract]   [Full Text] [Related]  

  • 23. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity.
    Connors TA; Whisson ME
    Nature; 1966 May; 210(5038):866-7. PubMed ID: 5958471
    [No Abstract]   [Full Text] [Related]  

  • 24. Structure-activity relationship of aniline mustards acting against B-16 melanoma in mice.
    Panthananickal A; Hansch C; Leo A
    J Med Chem; 1979 Oct; 22(10):1267-9. PubMed ID: 513075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of mutagenic and carcinogenic activities of aniline mustards.
    Leo A; Panthananickal A; Hansch C; Theiss J; Shimkin M; Andrews AW
    J Med Chem; 1981 Jul; 24(7):859-64. PubMed ID: 7277394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance study in a mixed nitrogen mustard-sensitive-resistant tumour.
    Ujházy V
    Neoplasma; 1969; 16(4):467-8. PubMed ID: 5344233
    [No Abstract]   [Full Text] [Related]  

  • 28. [Time factor in evaluating antineoplastic agents].
    Syrkin AB
    Farmakol Toksikol; 1972; 35(1):75-9. PubMed ID: 5011523
    [No Abstract]   [Full Text] [Related]  

  • 29. [Biological effects of 4-[N.N-bis-(2-chlorethyl)-amino]-phenyl-O-beta-D-glucopyranosiduronic acid methylesters].
    Tschiersch B; Schwabe K
    Pharmazie; 1977 Mar; 32(3):183-4. PubMed ID: 559313
    [No Abstract]   [Full Text] [Related]  

  • 30. The cytochemical demonstration of beta-glucuronidase in colon neoplasms of rats exposed to azoxymethane.
    Brown CA
    J Histochem Cytochem; 1978 Jan; 26(1):22-7. PubMed ID: 621376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysosomal enzymes in macrophages of colonic tumors induced in rats by 1,2-dimethylhydrazine dihydrochloride.
    Abraham R; Barbolt TA
    Cancer Res; 1978 Sep; 38(9):2763-7. PubMed ID: 209889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of 3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam-p-bis(2-chloroethyl)aminophenoxyacetate (NSC 294859) on experimental animal tumor and leukemia systems.
    Catsoulacos P
    Oncology; 1983; 40(4):290-2. PubMed ID: 6866424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biology of large solid tumours regressing with nitrogen mustard treatment: a study of the mouse plasma cell tumour Adj-pc-5 and the Walker carcinosarcoma 256.
    Goldacre RJ; Whisson ME
    Br J Cancer; 1966 Dec; 20(4):801-12. PubMed ID: 5964610
    [No Abstract]   [Full Text] [Related]  

  • 34. Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
    Teller MN; Bowie M; Mountain IM; Stock CC
    J Natl Cancer Inst; 1974 Mar; 52(3):667-71. PubMed ID: 4857022
    [No Abstract]   [Full Text] [Related]  

  • 35. Attempted targeting of a monoclonal antibody in a human tumour xenograft system.
    Warenius HM; Galfre G; Bleehen NM; Milstein C
    Eur J Cancer Clin Oncol; 1981 Sep; 17(9):1009-15. PubMed ID: 7198983
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Gd(III)-based receptor-induced magnetization enhancement (RIME) contrast agent for β-glucuronidase activity profiling.
    Chen SH; Kuo YT; Singh G; Cheng TL; Su YZ; Wang TP; Chiu YY; Lai JJ; Chang CC; Jaw TS; Tzou SC; Liu GC; Wang YM
    Inorg Chem; 2012 Nov; 51(22):12426-35. PubMed ID: 23116118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice.
    Sheard CE; Double JA; Berenbaum MC
    Br J Cancer; 1971 Dec; 25(4):838-44. PubMed ID: 5144544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.
    Stephens TC; Courtenay VD; Mills J; Peacock JH; Rose CM; Spooner D
    Br J Cancer; 1981 Apr; 43(4):451-7. PubMed ID: 7236488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
    Bibby MC; Double JA; Wahed IA; Hirbawi N; Baker TG
    Br J Cancer; 1988 Aug; 58(2):139-43. PubMed ID: 3166903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.